Mode
Text Size
Log in / Sign up
Phase 4 N=388 Randomized Double-blind Treatment

Study of Asthma and Nasal Steroids

Asthma · Rhinitis · Sinusitis

Enrolled (actual)
388
Serious AEs
2.8%
Results posted
Nov 2015
Primary outcome: Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Mometasone Furoate monohydrate (Drug); Placebo (Other)
Age
Pediatric, Adult, Older Adult · 6+ yrs
Sex
All
Sponsor
JHSPH Center for Clinical Trials
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Asthma Control Test (ACT)
2.95; 2.44
SECONDARY
Childhood Asthma Control Test
4.15; 4.53

Summary

The trial will study the effectiveness of nasal steroids for the treatment of chronic rhinitis and/or sinusitis on asthma control.

Eligibility Criteria

Inclusion Criteria

  • Physician diagnosed asthma
  • At least 12% increase in forced expiratory volume at one second (FEV1) after 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 16 mg/ml methacholine); either of these can be available from the last 2 years before enrollment
  • Poorly controlled asthma as documented by a score of 19 or less on the Asthma Control Test (ACT) for participants 12 and older, and a Childhood Asthma Control Test (C-ACT) for 6-11 years(both V1 and V2).
  • Chronic symptoms of rhinitis and sinusitis as measured by a mean score of 1 on the Sino-nasal questionnaire
  • Males and females, age 6 and older

Exclusion Criteria

  • Co-morbidity that predisposes to complicated rhino-sinusitis (e.g., cystic fibrosis, insulin dependent diabetes mellitus, immunodeficiency disorder)
  • Chronic diseases (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney or nervous system.
  • History of sinus surgery in last 6 months
  • Systemic/nasal steroids within last 4 weeks
  • Anti-leukotriene medication
  • History of upper airway symptoms for less than 8 weeks at the time of enrollment
  • Fever > 38.3 degrees Celsius or patient history of fever in last 10 days
  • Greater than 10 pack year smoking history or active smoking within the last 6 months
  • FEV1 < 50% predicted
  • Females of childbearing potential that are pregnant or lactating, or unwilling to practice an adequate birth control method
  • Allergy or intolerance to nasal mometasone
  • Cataracts, history of glaucoma, or other conditions resulting in increased intraocular pressure
  • Any investigational drug in the last 6 weeks
  • Inability to comply with study procedures, including:
  • Inability or unwillingness to provide informed consent (or assent in the case of a minor)
  • Inability to take study medication
  • Inability to perform baseline measurements
  • Completion of less than 10 of the 14 days of screening period diary entry
  • Inability to be contacted by phone
  • Intention to move out of the area within 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01118312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search